Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
about
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationAssessment of pancreatic β-cell function: review of methods and clinical applicationsDPP-4 inhibition and islet functionSitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic miceTherapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once-daily injection of insulin glargine in non-obese diabetic mice.Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic ratsGeneration of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease.Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.A simple matter of life and death-the trials of postnatal Beta-cell mass regulationDeletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell massEffects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation.Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.Gastrointestinal hormones and the regulation of β-cell mass.GAD-alum immunotherapy in Type 1 diabetes mellitus.Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation.GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents:Platyconic acid, a saponin from Platycodi radix, improves glucose homeostasis by enhancing insulin sensitivity in vitro and in vivo.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats.Sitagliptin protects proliferation of neural progenitor cells in diabetic mice.Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials.Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: Effects on peripheral sensory nerve function, structure and molecular changes.
P2860
Q26778329-144606AC-9519-484A-86FD-5FFE9F994BD1Q26829445-BF47E1A2-AA01-4022-B50C-C567B29B1674Q27028127-7DC26510-A7D0-44E5-B1AD-5A16B29E6C6AQ33562131-22336F32-22AB-459D-9B6B-EBD125ED963EQ33603301-139FC735-2AFE-419A-9346-166FB6E6AC1DQ33609788-B7D6A8C1-D68D-41C7-9DDB-09DA20FB0FDEQ34003019-7D3BB002-BEA4-40EC-B041-4129B7BCE6A1Q34073469-C9A4E6C5-397F-4A8F-98EF-C9F5A34FC470Q34219918-F316E445-7109-40A4-9D7B-C1DB82F40287Q34273302-26CF5F39-AE68-4A07-8B10-915384253F10Q34278297-916F4B24-9527-4B75-8F60-74CECB451E3EQ34597496-9666266F-03DB-4219-81EF-1040F910CC98Q35070417-23F37E14-A19F-4EB9-9239-C4A8DCD75A1CQ35125198-0A4FEF20-E18F-4E1D-8285-C0590445D65FQ35193875-CBC11BB8-E830-4003-9B29-3DD3959F1B73Q35487986-28E52E90-4BC7-46ED-9C7B-5F65C01FFC7AQ35860311-8F7A4D92-35E6-4B3F-8CE9-8B2528F614B7Q35942505-9D4B2444-482C-4B03-AB05-D49776B1A2C9Q36016914-4A3CE3E4-C5A4-4C3C-B9E4-9A161FC32C94Q36315963-71157127-68A5-44C1-AB07-94088B1D4D08Q37164446-01421AB8-A40D-4754-8AFE-89E1554C4073Q37476451-A637BD27-7F4F-4D9D-8418-FE7F754DFA80Q37730690-93F24737-17C8-495F-8318-B08E4F4202F1Q37772523-A65D8E78-2680-4A6B-A3A4-0A25C1CBE0A0Q37805600-19F4A5B6-EBD0-4A26-8FFA-3DAB11DB4E81Q37851966-A7C734D1-381B-45D3-AFA9-16C0C0F2871DQ37857686-BE5274E6-EE45-4BDA-8E0B-40100ADDDB22Q37900690-DD7037F8-BF27-46CC-8CDD-4AA6E0821F66Q38747179-249DD46E-5026-43D2-A7FF-D1F2C9FE6205Q39237033-5DC25DFE-F1AF-457A-8417-452162B46F45Q41097981-09DB293B-D311-450A-82F2-EC2C627BFC93Q42806768-03BCE93D-98D1-40DD-80C9-664D9106FF76Q42876331-B57FD182-6997-45CB-B353-532875965AE5Q45778975-E6E5B4BD-F177-4AFD-845D-C1AF1D257C04Q45985301-DAFC16DD-BDF0-41A9-8759-2593D3FD16C2Q48167168-B783F147-FD7E-46E4-A849-133DFE935BFBQ48321628-A1E7650D-5A39-4B96-B936-A40153CDBAFEQ48376252-AF91FFFF-03C9-4011-B29C-B4621BBA3B11Q48379621-C2E3BEF2-60DD-4205-A45D-F119CFB19420Q48713671-6A706C04-1AE1-41DA-A28C-62DC502685C9
P2860
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@en
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@nl
type
label
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@en
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@nl
prefLabel
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@en
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@nl
P2093
P1476
Inhibition of DPP-4 with sitag ...... dent model of type 2 diabetes.
@en
P2093
Aleksandr Petrov
Andrew D Howard
Bei B Zhang
Emanuel Zycband
George J Eiermann
John Woods
Nancy A Thornberry
P304
P356
10.1016/J.EJPHAR.2009.09.027
P407
P577
2009-09-16T00:00:00Z